NFE2L2 and malignant colon neoplasm: Li et al. investigated the potential of S-allylmercaptocysteine (SAMC) as an adjuvant to rapamycin in the treatment of colon cancer, with a particular focus on the interplay between Nrf2 and autophagy in the context of combination therapy 144.